Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Once-daily
100%
Valsartan
100%
Twice-daily Dosing
100%
Stable Heart Failure
100%
Heart Failure Patients
33%
NYHA Class
33%
Tolerability
16%
Moderate to Severe
16%
Heart Failure
16%
Twice Daily
16%
Maximum Tolerated Dose
16%
Blood Pressure
16%
Beta-blockers
16%
Hypotension
16%
Double-blind Trial
16%
Cystatin C (Cys C)
16%
Renal Impairment
16%
Creatinine
16%
Plasma Renin Activity
16%
Estimated Glomerular Filtration Rate
16%
Diuretics
16%
Clinical Parameters
16%
Brain Natriuretic Peptide
16%
Digoxin
16%
Biochemical Parameters
16%
Relative Efficacy
16%
Relative Safety
16%
Aldosterone Antagonists
16%
Orthostatic Dizziness
16%
RAAS Blockade
16%
Angiotensin-converting Enzyme Inhibitor (ACEi)
16%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Valsartan
100%
Tolerability
16%
Aldosterone Antagonist
16%
Beta Adrenergic Receptor Blocking Agent
16%
Dipeptidyl Carboxypeptidase Inhibitor
16%
Creatinine
16%
Hypotension
16%
Potassium Ion
16%
Dizziness
16%
Renin
16%
Brain Natriuretic Peptide
16%
Digoxin
16%
Cystatin C
16%
Diuretics
16%